Indeed, bortezomib, a proteasome inhibitor that exerted its antileukemic action through Notch1 downregulation, was highly synergistic with doxorubicin in several cell models of T-ALL [382]. The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.